Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on Accenture, Raises Price Target to $340

Citigroup analyst Ashwin Shirvaikar maintains Accenture (NYSE:ACN) with a Buy and raises the price target from $310 to $340.

byBenzinga Newsdesk

June 25, 2021

1 minute read

Citigroup analyst Ashwin Shirvaikar maintains Accenture (NYSE:ACN) with a Buy and raises the price target from $310 to $340.

Here’s How Much You Would Have Made Owning Abiomed Stock In The Last 15 Years

By Benzinga Insights

Today, 4:07 AM

Abiomed (NASDAQ:ABMD) has outperformed the market over the past 15 years by 18.87% on an annualized basis producing…

ABMD

Broadcom’s Vmware Draws More Regulatory Attention, This Time From EU

By Anusuya Lahiri

Today, 4:07 AM

U.S. chipmaker Broadcom Inc’s (NASDAQ:AVGO) $61 billion Vmware, Inc (NYSE:VMW) deal could hit a roadblock with EU antitrust regulators poised to open…

AMZN

Ocuphire Invited To Present Clinical Data On Nyxol And APX3330 At American Academy Of Ophthalmology 2021 Annual Meeting And Eyecelerator/AAO Meeting

By Benzinga Newsdesk

Today, 4:07 AM

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that

OCUP

U.S., Allies Agree on Which Sales of Russian Oil Are Subject to Price Cap

By Charles Gross

Today, 4:07 AM

-Wall Street Journal

RSX

Citigroup Maintains Buy on Accenture, Raises Price Target to $340

Related Posts

Here’s How Much You Would Have Made Owning Abiomed Stock In The Last 15 Years

Broadcom’s Vmware Draws More Regulatory Attention, This Time From EU

Ocuphire Invited To Present Clinical Data On Nyxol And APX3330 At American Academy Of Ophthalmology 2021 Annual Meeting And Eyecelerator/AAO Meeting

U.S., Allies Agree on Which Sales of Russian Oil Are Subject to Price Cap